Insight Molecular Diagnostics Inc. (iMDx), formerly known as Oncocyte Corporation, reported a significant increase in revenue for the fiscal year ending December 31, 2025, with total net revenue reaching $4.1 million, up from $1.9 million in 2024, marking a 116% increase. The growth was primarily driven by the company's Laboratory Services, which generated approximately $4.0 million from a single customer. Despite this revenue growth, iMDx reported a net loss of $50.2 million, an improvement from the $60.7 million loss in the previous year, attributed to decreased impairment losses and increased revenue, although offset by rising operating expenses.
The company has made strategic advancements, including the rebranding of its product lines and a focus on the organ transplant market. iMDx's flagship product, GraftAssureCore, received positive coverage from the Centers for Medicare & Medicaid Services (CMS) in August 2023, and the company has since expanded its offerings to include GraftAssureIQ and GraftAssureDx, with the latter currently under development. The company also entered into a Specimen Collection Agreement with a national reference lab provider in February 2026, which is expected to enhance its operational capabilities.
Operationally, iMDx has seen a rise in research and development expenses, which totaled $15.9 million in 2025, up from $9.8 million in 2024. This increase reflects the company's commitment to advancing its diagnostic tests, particularly in the transplant category. The workforce has remained stable, with 58 employees as of December 31, 2025. The company is also focused on expanding its market presence, particularly in the organ transplant sector, which is estimated to be a $2 billion market.
Looking ahead, iMDx anticipates continued investment in research and development, particularly for its transplant products, while also navigating the complexities of reimbursement from Medicare and private payers. The company has expressed concerns about potential changes in reimbursement policies that could impact its financial performance. iMDx's management remains optimistic about its growth trajectory, contingent on successful product commercialization and regulatory approvals. The company plans to leverage its strategic partnership with Bio-Rad Laboratories to enhance its product offerings and market reach.
About Insight Molecular Diagnostics Inc.
Oncocyte Corporation develops molecular diagnostic tests for transplant rejection and cancer therapy response. Its core products include blood-based assays for organ damage detection and oncology biomarkers, serving hospitals, transplant centers, and research institutions. The company leverages proprietary technology, strategic partnerships, and intellectual property to enable decentralized testing, aiming to improve patient outcomes, reduce healthcare costs, and foster innovation in personalized medicine.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.